Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis
The mannose-grafted nanovaccine shows promise in enhancing immune responses against pancreatic cancer in mouse models, but further research is needed to confirm its effectiveness and safety in humans.
Where it sits
this study against the rest of the pe 22-28 corpusSummary and findings
This study investigates a mannose-grafted nanovaccine platform aimed at enhancing immune responses against pancreatic ductal adenocarcinoma (PDAC). The nanovaccine co-packages CEACAM5 and immune adjuvants to improve antigen presentation and T-cell activation. Results indicate significant suppression of tumor growth and metastasis in a PDAC mouse model.
Abstract
<title>Abstract</title> <p>Pancreatic ductal adenocarcinoma (PDAC) is lethal in ~88% of patients. Immunotherapy has revolutionized cancer therapy for many cancer types; however, PDAC survival rates remain unchanged. Low tumor mutation burden, inefficient antigen presentation, limited response rates to standard-of-care (SoC) therapy, acquired resistance, and a profoundly immunosuppressive microenvironment constrain the efficacy of immunotherapy. Advances in nanotechnology-based vaccines have enabled the precise delivery of mRNA and antigens, thereby potently activating the immune system and opening new avenues for treating PDAC. Here, we report a mannose-grafted nanovaccine (NV) platform that co-packages the gastrointestinal cancer-overexpressed CEACAM5 (CEA5), and immune adjuvants to sensitize antigen-presenting cells (APCs) and enhance their antigen-presenting capacity, promoting efficient lymph node priming and robust CD4⁺ and CD8⁺ T-cell activation. Our NV induced substantial remodeling of the PDAC microenvironment, reflected by increased CD8+ T-cell infiltration and T-cell memory, while decreasing T-cell exhaustion, cancer-associated fibroblast abundance, desmoplasia, pro-tumorigenic metabolic pathways, and angiogenic signaling. NV monotherapy significantly suppressed primary tumor growth and extended survival in a PDAC mouse model. In a tumor resection model, NV-treated mice showed reduced local tumor recurrence and complete prevention of hepatic metastasis. Combination therapy with SoC and a KRAS inhibitor further enhanced tumor control and survival compared with either monotherapy. The translational potential of the NV is supported by patient-derived models, in which NV-pulsed APCs generated functional antigen-specific T cells capable of killing tumor cells. Notably, NV also demonstrated robust antitumor efficacy in a mouse colorectal cancer model, delaying tumor progression and prolonging survival, highlighting the translational potential of this modular platform across gastrointestinal cancers. Collectively, this work establishes a modular and translationally relevant NV platform capable of converting immune-refractory PDAC into a therapeutically responsive disease by amplifying endogenous antitumor immunity.</p>
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
- Not reported in abstract.